Table 2
Open in new tab

Variables associated with ES recurrence in ablated patients

ES recurrenceNo new ESP
LVEF (%)25 (22.5–32.5)35 (30–40)0.023
Age (years)72 (47–77)68 (62–73)0.7
Creatinin (mg/dl)1.1 (0.9–1.3)1.2 (1–1.7)0.2
LVEDD (mm)63 (60–66)56 (51–68)0.2
NYHA2 (1.3–2.8)2 (2–2)0.8
BB (%)62601
ARB (%)100730.68
EPOC (%)13370.29
Diabetics (%)25331
Previous SVT (%)25201
ES recurrenceNo new ESP
LVEF (%)25 (22.5–32.5)35 (30–40)0.023
Age (years)72 (47–77)68 (62–73)0.7
Creatinin (mg/dl)1.1 (0.9–1.3)1.2 (1–1.7)0.2
LVEDD (mm)63 (60–66)56 (51–68)0.2
NYHA2 (1.3–2.8)2 (2–2)0.8
BB (%)62601
ARB (%)100730.68
EPOC (%)13370.29
Diabetics (%)25331
Previous SVT (%)25201

Continuous variables are shown as median (interquartilic range).

LVEDD, left ventricle end diastolic diameter; BB, beta-blocker; ARB, angiotensin receptor blockers; EPOC, chronic obstructive bronchitis.

Table 2
Open in new tab

Variables associated with ES recurrence in ablated patients

ES recurrenceNo new ESP
LVEF (%)25 (22.5–32.5)35 (30–40)0.023
Age (years)72 (47–77)68 (62–73)0.7
Creatinin (mg/dl)1.1 (0.9–1.3)1.2 (1–1.7)0.2
LVEDD (mm)63 (60–66)56 (51–68)0.2
NYHA2 (1.3–2.8)2 (2–2)0.8
BB (%)62601
ARB (%)100730.68
EPOC (%)13370.29
Diabetics (%)25331
Previous SVT (%)25201
ES recurrenceNo new ESP
LVEF (%)25 (22.5–32.5)35 (30–40)0.023
Age (years)72 (47–77)68 (62–73)0.7
Creatinin (mg/dl)1.1 (0.9–1.3)1.2 (1–1.7)0.2
LVEDD (mm)63 (60–66)56 (51–68)0.2
NYHA2 (1.3–2.8)2 (2–2)0.8
BB (%)62601
ARB (%)100730.68
EPOC (%)13370.29
Diabetics (%)25331
Previous SVT (%)25201

Continuous variables are shown as median (interquartilic range).

LVEDD, left ventricle end diastolic diameter; BB, beta-blocker; ARB, angiotensin receptor blockers; EPOC, chronic obstructive bronchitis.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close